Neda Amini

surgical oncologist@Geisinger health former fellow@NorthwellHealth, researcher, biostatistics, love dancing and cooking.

[Annals of Surgery @AnnalsofSurgery]

Among patients with clinically staged T1 ampullary cancer, more than two-thirds were upstaged to a higher pathologic T stage and nearly half were found to have nodal disease at resection. https://t.co/0UguL9dpiA

[Neda Amini @Nedamini]

Early Enteral vs Oral Postoperative Nutrition After Pancreatoduodenectomy https://t.co/wcvsXM3Ygl

[Neda Amini @Nedamini]

Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer | Cancer Biomarkers | JAMA Surgery | JAMA Network https://t.co/h9683AZI1t

[Neda Amini @Nedamini]

BREAKWATER Update: Encorafenib + Cetuximab + FOLFIRI Improves PFS, Lengthens OS in BRAFV600E–Mutant mCRC https://t.co/I09qja4Sfw

[Neda Amini @Nedamini]

EMERALD-3: Tremelimumab + Durvalumab Improves Clinical Outcomes When Combined With SOC in Unresectable HCC https://t.co/gPOftScRPV

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠�� Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[Neda Amini @Nedamini]

If you are interested in global surgery topic, please join us in upcoming webinar

[Erin Dickey, MD, MBS @DrEMDickey]

Super excited to win first place for outstanding research for our MyCode HRD in PDAC project at Geisinger Department of Surgery Research Day alongside my chief! 💪 Amazing showing from the General Surgery Residents this year, so proud of this team! 🩺✨

[Neda Amini @Nedamini]

Best part of academic surgery is mentoring and working with talented residents !! Congrats Erin!! well deserved! You will make a great surgical oncologist!

[Erin Dickey, MD, MBS @DrEMDickey]

Truly honored to receive the Poster of Distinction award at #PancreaClub2026! 🏆

It’s been a rewarding challenge to bridge the gap between lab and clinic, this research was initiated while transitioning back into residency. Grateful for the support!

[Neda Amini @Nedamini]

RFA and Chemotherapy in Locally Advanced Pancreatic Cancer https://t.co/Wbhi75POzB

[Neda Amini @Nedamini]

@ZhiVenFongMD It is absurd …

[Angela Lamarca @DrAngelaLamarca]

Waiting for two abstracts to be presented the whole @AACR #AACR26, this is one of them

Just presented, #Daraxonrasib in #mKRAS #PDAC by @EileenMOReilly

#Monotherapy in the #FirstLine
38 pts
ORR 47%
Time on tto 7.7m
PFS immature

Ongoing Phase III 303 (Dara vs GemNab+/-Dara)

[Neda Amini @Nedamini]

Interesting case, 72 yo with 4 cm pancreatic cyst. CA 19-9 WNL, no other red flags.
Guidelines might say “watch.”
NGS on EUS suspicious
Surgery → focal adenocarcinoma.
We’re missing cancers or HGD if we ignore molecular data.
NGS deserves a seat in the guidelines. #HPB

[Neda Amini @Nedamini]

Surgical management of small intestinal neuroendocrine tumours | BJS | Oxford Academic https://t.co/vprZLrJf1J

[Julie Hallet @HalletJulie]

PanNETs @BJSurgery Commission: operate on small NF PanNETs ≤2 cm?

⏱️With typical features - observation safe
📊PANDORA &amp; ASPEN: rare progression, no survival compromise
🔪Surgery for atypical features (MPD⬆️, heterogeneity, ⬆️nodes)

🔗https://t.co/fqS90z6MkO

@spartelli

[Neda Amini @Nedamini]

@HalletJulie @OscarGuevaraHPB @BJSurgery @spartelli @BJSAcademy @NANETS1 @ENETS_ORG @IHPBA @DrCNClarke @JMaxCutsNETs @AleBuerba @ksoreide @valentinandreas @helops79 @halletjulie how about multiple small NET between 1-2 cm ? Should it be considered as atypical feature?

[Neda Amini @Nedamini]

The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study: Results from a Worldwide Survey | Annals of Surgical Oncology | Springer Nature Link https://t.co/OOK5rX4WSz

[Syed A. Ahmad @SyedAAhmad5]

First in human kras G12D degrader. 👇🏼👇🏼

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer https://t.co/2mUQxTLFIe

[Neda Amini @Nedamini]

Prolonged Prophylactic Antibiotics Based on Preoperative Bile Culture Reduce Surgical Site Infections After Pancreaticoduodenectomy Following Preoperative Biliary Drainage: A Propensity‐Matched Analysis - Matsumoto - 2026 https://t.co/Gi8aV0nqJZ